Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles

International Journal of Pharmaceutics

Volumn 389, Issue 1-2, 2010, Pages 223-231

  Ali, Hazem ^a   Shirode, Amit B ^a   Sylvester, Paul W ^a   Nazzal, Sami ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Cancer therapy; Drug delivery; Nanoparticle; Simvastatin; Tocotrienol

Indexed keywords

ALPHA TOCOTRIENOL; NANOPARTICLE; SIMVASTATIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST EPITHELIUM; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; EPITHELIUM CELL; FEMALE; IC 50; LIPOPHILICITY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG STABILITY; DRUG STORAGE; FEMALE; INHIBITORY CONCENTRATION 50; LIPIDS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; SIMVASTATIN; TIME FACTORS; TOCOTRIENOLS; X-RAY DIFFRACTION;

EID: 77349111008     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.01.018     Document Type: Article

References (37)

1. Ahlin P., Kristl J., and Šmid-Kober J. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm. 48 (1998) 257-267
2. Ali H., and Nazzal S. Development and validation of a reversed-phase HPLC method for the simultaneous analysis of simvastatin and tocotrienols in combined dosage forms. J. Pharm. Biomed. Anal. 49 (2009) 950-956
3. Bunjes H., and Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev. 59 (2007) 379-402
4. Campbell M.J., Esserman L.J., Zhou Y., Shoemaker M., Lobo M., Borman E., Baehner F., Kumar A.S., Adduci K., Marx C., Petricoin E.F., Liotta L.A., Winters M., Benz S., and Benz C.C. Breast cancer growth prevention by statins. Cancer Res. 66 (2006) 8707-8714
5. Castelli F., Puglia C., Sarpietro M.G., Rizza L., and Bonina F. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int. J. Pharm. 304 (2005) 231-238
6. Danielson K.G., Anderson L.W., and Hosick H.L. Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res. 40 (1980) 1812-1819
7. Dong X., Mattingly C.A., Tseng M., Cho M., Adams V.R., and Mumper R.J. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur. J. Pharm. Biopharm. 72 (2009) 9-17
8. Freitas C., and Muller R.H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersions. Int. J. Pharm. 168 (1998) 221-229
9. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
10. Graaf M.R., Richel D.J., van Noorden C.J., and Guchelaar H.J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30 (2004) 609-641
11. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. Physico-chemical stability of colloidal lipid particles. Biomaterials 24 (2003) 4283-4300
12. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., and Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 4607-4612
13. Jenning V., Mader K., and Gohla S.H. Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a (1)H-NMR study. Int. J. Pharm. 205 (2000) 15-21
14. Kaneko I., Hazama-Shimada Y., and Endo A. Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur. J. Biochem. 87 (1978) 313-321
15. Kotamraju S., Williams C.L., and Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 67 (2007) 7386-7394
16. Koyuturk M., Ersoz M., and Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett. 250 (2007) 220-228
17. Lai F., Wissing S.A., Muller R.H., and Fadda A.M. Artemisia arborescens L essential oil-loaded solid lipid nanoparticles for potential agricultural application: preparation and characterization. AAPS PharmSciTech 7 (2006) E2
18. Ma P., Dong X., Swadley C.L., Gupte A., Leggas M., Ledebur H.C., and Mumper R.J. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol. 5 (2009) 151-161
19. Maltese W.A., Defendini R., Green R.A., Sheridan K.M., and Donley D.K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Clin. Invest. 76 (1985) 1748-1754
20. McIntyre B.S., Briski K.P., Gapor A., and Sylvester P.W. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc. Soc. Exp. Biol. Med. 224 (2000) 292-301
21. McIntyre B.S., Briski K.P., Tirmenstein M.A., Fariss M.W., Gapor A., and Sylvester P.W. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 35 (2000) 171-180
22. Muller R.H., Radtke M., and Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242 (2002) 121-128
23. Pasqualini R., Arap W., and McDonald D.M. Probing the structural and molecular diversity of tumor vasculature. Trends Mol. Med. 8 (2002) 563-571
24. Samant G.V., and Sylvester P.W. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell. Prolif. 39 (2006) 563-574
25. Sassano A., and Platanias L.C. Statins in tumor suppression. Cancer Lett. 260 (2008) 11-19
26. Schwarz C., Mehnert W., Lucks J.S., and Muller R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control. Release 30 (1994) 83-96
27. Serpe L., Catalano M.G., Cavalli R., Ugazio E., Bosco O., Canaparo R., Muntoni E., Frairia R., Gasco M.R., Eandi M., and Zara G.P. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 58 (2004) 673-680
28. Shah S., and Sylvester P.W. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp. Biol. Med. (Maywood) 229 (2004) 745-755
29. Shah S., Gapor A., and Sylvester P.W. Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr. Cancer 45 (2003) 236-246
30. Shibata M.A., Kavanaugh C., Shibata E., Abe H., Nguyen P., Otsuki Y., Trepel J.B., and Green J.E. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24 (2003) 453-459
31. Souto E.B., Mehnert W., and Muller R.H. Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul. 23 (2006) 417-433
32. Teeranachaideekul V., Souto E.B., Junyaprasert V.B., and Muller R.H. Cetyl palmitate-based NLC for topical delivery of coenzyme Q(10)-development, physicochemical characterization and in vitro release studies. Eur. J. Pharm. Biopharm. 67 (2007) 141-148
33. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., Trepel J., Liang B., Patronas N., Venzon D.J., Reed E., and Myers C.E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2 (1996) 483-491
34. Wali V.B., and Sylvester P.W. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids 42 (2007) 1113-1123
35. Wali V.B., Bachawal S.V., and Sylvester P.W. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp. Biol. Med. (Maywood) 234 (2009) 639-650
36. Wong H.L., Bendayan R., Rauth A.M., Li Y., and Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 491-504
37. Yuan H., Miao J., Du Y.Z., You J., Hu F.Q., and Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 348 (2008) 137-145